More Bleeds in Practice Than Expected

November 5, 2014 7:57 PM

4 0

Dabigatran (Pradaxa) was associated with higher risk of bleeding than warfarin (Coumadin) in a large Medicare population sample, unlike the equal risk seen in the pivotal RE-LY trial.

The relative risk was 30% higher for any bleeding with the direct thrombin inhibitor than warfarin and 58% higher for major bleeding (propensity adjusted rate 9.0% versus 5.9%, P<0.001), Yuting Zhang, PhD, of the University of Pittsburgh, and colleagues reported online in JAMA Internal Medicine.

Read more

To category page